Immunotherapies targeting immune checkpoint molecules such as PD-1 (programmed cell death 1), PD-L1 (programmed cell death 1-ligand 1), and CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) may be effective treatments for mesothelioma [17]. This evidence concerns the gene CTLA4 and mesothelioma.